Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00307125 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv14
  2. Results first posted: Mar 23, 2015v13 Show 8 more changesShow less
    • Primary endpoints: 2 to 3
    • Interventions: Rituximab (Drug) to Placebo plus immunosuppression (Drug), Rituximab plus immunosuppression (Drug)
    • Secondary endpoints: 12 to 7
    • Study description expanded, about 103 words
    • Collaborators expanded, about 11 words
    • Study title expanded, about 8 words
    • Study arms: 1 to 2
    • Eligibility criteria shortened, about 4 words
  3. Trial status: Active, Not Recruiting to Completed
    • Primary completion date changed from estimate of Dec 2013 to Dec 2012
    • Study completion date changed from estimate of Dec 2014 to Dec 2012
    v12
  4. Primary completion date: Dec 2012 to Dec 2013v11 Show 7 more changesShow less
    • Primary endpoints revised (2)
    • Enrollment target: 780 to 757
    • Study sites: 19 to 17
    • Study completion date: Mar 2014 to Dec 2014
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: 8 to 12
    • Study description expanded, about 2 words
  5. Primary completion date: Mar 2014 to Dec 2012v10 Show 10 more changesShow less
    • Primary endpoints: 1 to 2
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 134 to confirmed 780
    • Study sites: 20 to 19
    • Study completion date: Mar 2014
    • Interventions: Immunosuppressive drugs (Drug), Rituximab (Drug) to Rituximab (Drug)
    • Secondary endpoints: 9 to 8
    • Study description shortened, about 64 words
    • Study arms: 2 to 1
    • Eligibility criteria expanded, about 1 word
Show 8 earlier versionsHide 8 earlier versions
  1. Study sites: 17 to 20
    • Eligibility criteria shortened, about 6 words
    • Study description expanded, about 91 words
    v9
  2. Re-verified, no change to tracked fieldsv8
  3. Site details revised at 2 of 17 sitesv7
  4. Site details revised at 8 of 17 sitesv6
  5. Enrollment target: 434 to 134v5 Show 7 more changesShow less
    • Primary endpoint revised
    • Study sites: 6 to 17
    • Primary completion date: Mar 2014
    • Secondary endpoints revised (9)
    • Study description shortened, about 89 words
    • Study arms: 0 to 2
    • Eligibility criteria expanded, about 3 words
  6. 2 versions Re-verified since Sep 8, 2006, no change to tracked fieldsv3-v4
  7. Study description expanded, about 2 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine whether treatment with rituximab (anti-CD20, Rituxan®, MabThera®) in individuals who develop new anti-HLA antibodies after renal (kidney) transplant will promote longer-term survival of the transplanted kidney.The pilot study compares the use of rituximab (Rituxan®) + site-specific standard immunosuppression to placebo + site-specific standard immunosuppression in the treatment of circulating anti-HLA antibodies in subjects who develop de novo anti-HLA antibodies between 3-36 months after transplant.
Trial Details
NCT Number NCT00307125
Lead Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: Clinical Trials in Organ Transplantation, Cooperative Clinical Trials in Pediatric Transplantation
Conditions
(from sponsor)		 Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
Enrollment 757 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov